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thoracic artery (ITA),1 the gastroepiploic artery,2 the
inferior epigastric artery,3 and the radial artery (RA).4
The ITA is probably the first choice for arterial grafts in
most institutions. A unique opinion with regard to the
A utologous arteries have been used as grafts for coro-nary artery bypass grafting (CABG) and have
gained popular use recently.1-4 At the moment, 4 arter-
ies are the major arterial grafts. These are the internal
Objectives: The radial artery is spastic, and calcium channel antagonists
have been used clinically in the radial artery for their antispastic effects.
To choose a proper calcium channel antagonist for such a purpose, we
compared the in vitro antispastic effects of 4 clinically used calcium
channel antagonists (nicardipine, nifedipine, verapamil, and diltiazem)
in the human radial artery. Methods: Radial artery segments taken from
patients undergoing coronary bypass operations were studied in the
organ bath. The relaxation by the calcium channel antagonists was com-
pared in the potassium-precontracted (25 mmol/L) radial artery. The
inhibitory effect of the calcium channel antagonists at the clinically rel-
evant plasma concentration and a higher concentration was also studied
for the calcium channel antagonists. Results: All calcium channel antag-
onists induced a full relaxation (97.8%-100%, n = 5-7 for each), with
higher sensitivity (P = .005, analysis of variance [ANOVA] among the
calcium channel antagonists for the effective concentration of the con-
strictor [or dilator] agent that caused 50% of maximal contraction [or
relaxation]) to nifedipine (–7.37 ± 0.20 log10 M) than nicardipine (–6.43
± 0.39 log10 M, P = .1), verapamil (–6.08 ± 0.13 log10 M, P = .03), and dil-
tiazem (–5.87 ± 0.07 log10 M, P = .01). Pretreatment with the plasma con-
centration of the calcium channel antagonists (60 nmol/L for diltiazem
and 20 nmol/L for the others) inhibited the potassium-induced contrac-
tion (n = 6 for each) by nicardipine (from 138.6% ± 5.8% to 101.4% ±
7.6%, P = .001) and nifedipine (to 87.7% ± 6.8%, P = .0003) but not by
verapamil (to 140.3% ± 15.2%, P = .9) or diltiazem (to 132.8% ± 7.3%,
P = .8), although at higher contractions (–4.5 log10 M) all 4 calcium
channel antagonists abolished the contraction. Conclusions: Although all
calcium channel antagonists have antispastic effects in the radial artery,
the vessel has different sensitivities to them. Dihydropyridine derivatives
may be the most potent calcium channel antiagonists and therefore are
recommended for the clinical use for this purpose. (J Thorac Cardiovasc
Surg 2000;119:94-100)
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second choice of arterial grafts has not been formed.
However, in some institutions4-6 and recently at the
University of Hong Kong, Grantham Hospital, the RA
has become the preferred arterial graft after the ITA.
We previously classified all arterial grafts into 3
types7: type I, somatic arteries; type II, splanchnic
arteries; and type III, limb arteries. Type II and III arter-
ies are more spastic than type I arteries. According to
this classification, the RA belongs to the type III arter-
ial graft and is more spastic than type I arteries, such as
the ITA.7-9 From our experience and in accordance with
that of others,4 the RA contraction (or spasm) is almost
inevitably encountered during the surgical dissection.
In fact, the revival of the RA was largely due to the use
of calcium channel antagonists.4 Diltiazem was used in
Acar and colleagues’4 initial surgical experience to
release RA spasm. We have recently developed an anti-
spastic protocol (University of Hong Kong protocol)
for using the RA as an arterial graft10 and have report-
ed its efficacy in the prevention and relief of
vasospasm11 and in the preservation of endothelium in
the RA.10 In the University of Hong Kong protocol,
verapamil is used. It is believed that use of calcium
channel antagonists played a key role in antispastic
therapy for the RA to obtain high patency and low inci-
dence of vasospasm.
There is a wide range of calcium antagonists.
Classically, there are 3 chemically divergent groups:
dihydropyridines (eg, nifedipine and nicardipine),
phenylalkylamines (eg, verapamil), and benzo-
thiazepines (eg, diltiazem). New calcium channel
antagonists structurally different from these 3 groups
have also been developed but are not yet used clinical-
ly. The choice of calcium channel antagonists for relief
of RA spasm has been empirical.4 We designed the pre-
sent study to compare the spasmolytic effect of 4 calci-
um channel antagonists currently used in the RA to
provide information for their clinical application. One
of the first-generation calcium channel antagonists
(nifedipine, verapamil, and diltiazem) from each of the
3 chemically divergent groups was studied. In addition,
because nifedipine is not available for intravenous infu-
sion, another clinically used dihydropyridine derivative
available for intravenous infusion (nicardipine) was
also studied.
Methods
General. Ninety-four human RA segments were collected
from 25 patients undergoing CABG with the RA. Approval to
use discarded RA tissue was given by the Grantham Hospital
Human Ethics Committee. Any redundant or discarded RA
segments were collected and placed in a container with oxy-
genated physiologic solution (Krebs solution) maintained at
4°C and then transferred to the laboratory immediately. The
RA was transferred into a glass dish and dissected out from
its surrounding connective tissue. The vessels were cut into 3-
mm long rings and suspended on wires in organ baths.12,13
The number of rings taken from each patient varied from 2 to
6. The Krebs’ solution had the following composition: 144
mmol/L Na+, 5.9 mmol/L K+, 2.5 mmol/L Ca2+, 1.2 mmol/L
Mg2+, 128.7 mmol/L Cl–, 25 mmol/L HCO3–, 1.2 mmol/L
SO42–, 1.2 mmol/L H2PO4–, and 11 mmol/L glucose. The
solution was aerated with a gas mixture of 95% oxygen and
5% carbon dioxide at 37°C.
Organ bath technique. A technique that allowed for vas-
cular rings to normalize to a physiologic pressure in the organ
bath was used in this study. The vascular rings were set at a
pressure comparable with that used in the in vivo situation.
The details of the technique were published before14,15 and
repeatedly used in in vitro studies for human vessels, includ-
ing the ITA and RA.7,9-13,15 Briefly, the rings were stretched
up in progressive steps to determine the length-tension curve
for each ring. A computer iterative fitting program (VES-
TAND 2.1; Yang-Hui He, Princeton, NJ) was used to deter-
mine the exponential line, pressure, and the internal diameter.
When the transmural pressure on the rings reached 100 mm
Hg, as determined from their own length-tension curves, the
stretch-up procedure was stopped, and the rings were
released to 90% of their internal circumference at 100 mm
Hg. This degree of passive tension was then maintained
throughout the experiment.
In this study the endothelium was intentionally preserved
by cautiously dissecting and mounting the rings because
endothelium plays a modulatory role in the contractility of
arterial grafts.13,14 We previously found that this technique
Table I. Potency (EC50) of calcium channel antagonists in relaxation of the human RA precontracted with potassium
(25 mmol/L)
Nifedipine Nicardipine Verapamil Diltiazem
EC50 (–log10 M) 7.37 ± 0.20 6.43 ± 0.38 6.08 ± 0.13 5.87 ± 0.07
95% CI of the mean difference of EC50 compared with nifedipine — –0.07 to 1.95 –1.85 to –0.72 –2.02 to 0.99
P value* — .06 .0006 .0001
EC50 is expressed in –log10 M. The difference between nifedipine and other calcium-channel antagonists is the 10difference-fold concentration. The P value is .005
among the 4 groups (ANOVA).
*Compared with nifedipine (unpaired t test).
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allowed for the experiments to be carried out with an intact
endothelium, as determined by the functional relaxation
response to acetylcholine or calcium ionophore in the human
arteries.9,10,12
Protocol. After the normalization procedure, the RA rings
were equilibrated for at least 1 hour. If more than one ring
was taken from the same patient, the vessels were randomly
assigned to different groups to maximally reduce the possible
influence to the results because of multiple rings from the
same patient allocated in a certain group of experiments. This
was feasible for the contraction studies. For the same reason,
in the relaxation studies multiple RA ring segments taken
from the same patient were also allocated to different treat-
ments whenever possible.
Relaxation. Calcium antagonist–induced relaxation was
studied in the precontraction induced by potassium (25
mmol/L). Cumulative concentration-relaxation curves to each
calcium channel antagonist were then established. Only one
concentration-relaxation curve was obtained from each RA
ring. From 6 rings (taken from 4-6 patients), a mean concen-
tration-relaxation curve was constructed.
Depression of contraction by pretreatment with calcium
antagonists. Using separate RA rings, after equilibration,
potassium (100 mmol/L) was added into the organ bath, and
the contraction force was recorded. The ring was frequently
washed to restore the baseline. To determine whether pre-
treatment with plasma concentrations of calcium channel
antagonists would alter the contraction response to potassi-
um, cumulative concentration-contraction curves were con-
structed with RA rings. The contraction was expressed as a
percentage of the contraction force induced by a 100-mmol/L
concentration of potassium. In contraction studies, whenever
possible, the rings from the same patient were allocated to
different groups in which the rings were treated with differ-
ent concentrations of the calcium channel antagonist. In these
experiments one group of RA segments served as controls
without pretreatment of calcium channel antagonists, and a
second group of RA segments was treated with one of the 4
calcium channel antagonists at plasma concentrations for 20
minutes before the concentration-contraction curves to potas-
sium were constructed. According to the literature, the free
plasma concentrations for nifedipine, verapamil,16 and
nicardipine17 have been measured at levels equivalent to
approximately 20 nmol/L, and that for diltiazem has been
measured at 60 nmol/L.16 These concentrations (20 nmol/L
for nifedipine, verapamil, and nicardipine and 60 nmol/L for
diltiazem) were chosen to study the inhibitory effect of calci-
um channel antagonists in the present study. To test the pos-
sible effect of higher concentrations (30 µmol/L) of calcium
channel antagonists, which can be reached for topical treat-
ment during surgery, RA rings were treated with calcium
channel antagonists in separate groups at these concentra-
tions for 20 minutes before the concentration-contraction
curves to potassium were constructed (n = 6 in each group).
Data analysis. The effective concentration of the constric-
tor (or dilator) agent that caused 50% of maximal contraction
(or relaxation) (EC50) was determined from each concentra-
tion-contraction (or relaxation) curve by a logistic, curve-fit-
ting equation:
E = MAp/(Ap + Kp) 
where E is response, M is maximal contraction (or relax-
ation), A is concentration, K is EC50 concentration, and p is
the slope parameter.14 A computerized program was used for
the curve fitting.
From this fitted equation, the mean EC50 value ± SEM was
calculated in each group. Unpaired t tests or analyses of vari-
ance were used to test statistical significance between differ-
ent constrictors and dilators regarding the maximal response
or EC50. The Scheffe F test was used as a post hoc test
between groups.
Drugs. All drugs used in this study were purchased from
Sigma Chemical Co (St Louis, Mo). Calcium antagonists
were freshly made in a glass vial and protected from light.
Results
Resting vessel parameters.14 The mean internal
diameter of the 94 rings at an equivalent transmural
pressure of 100 mm Hg was 2.7 ± 0.1 mm, as deter-
mined from the normalization procedure. When the RA
rings were set at a resting diameter of 0.9 times a trans-
mural pressure of 100 mm Hg, the equivalent trans-
mural pressure was 66.1 ± 1.7 mm Hg, and the resting
force was 2.3 ± 0.2 g.
Fig 1. Mean concentration (–log10 M) response (percentage
relaxation) curves for 4 calcium channel antagonists in the
human radial artery precontracted by potassium chloride (dil-
tiazem, potassium 25 mmol/L; n = 6 for nicardipine [NIC], n
= 6 for nifedipine [NIF], and n = 5 for verpamil [VER] and
diltiazem [DIL]). The rings were taken from 4 to 6 patients in
each group. Vertical error bars are 1 SEM of mean values.
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Relaxation by calcium antagonists in the potassi-
um-precontracted RA. The time course for the relax-
ation induced by each dose of the calcium channel
antagonist was 20 minutes. All 4 calcium channel
antagonists caused a full or nearly full relaxation in the
RA precontracted by potassium (25 mmol/L; P = .13,
ANOVA among the 4 calcium channel antagonists at
the maximal relaxation; Table I and Fig 1). However,
there was a significant difference with regard to the
EC50 (P = .005, ANOVA; Table I). Nifedipine is signif-
icantly more potent than either verapamil (P = .0006,
95% confidence interval [CI] for the mean difference:
–1.85 to –0.72 [–log10 M]) or diltiazem (P = .0001;
95% CI, –2.02 to 0.99 [–log10 M]; Table I). By com-
parison of the EC50 values at the actual concentration,
nifedipine is 19.5-fold more potent than verapamil (P =
.0006) and 31.6-fold more potent than diltiazem (P =
.0001). With regard to the potency of nicardipine, it is
marginally more potent than verapamil (2.2-fold high-
er, P = .8) and diltiazem (3.6-fold higher, P = .5,
Scheffe test).
Depression of contraction to potassium by pre-
treatment with calcium antagonists. With pretreat-
ment with calcium channel antagonists at these plasma
concentrations, the depressive effect of dihydropy-
ridines (nifedipine and nicardipine) was more signifi-
cant than that of verapamil and diltiazem. Both nifedi-
pine and nicardipine significantly depressed the
maximum contraction (P = .0002 for nifedipine and P
= .003 for nicardipine; Table II and Fig 2, A and B). In
contrast, neither verapamil (P = .9) nor diltiazem (P =
.5) reduced the maximum contraction (Table II and Fig
2, C and D).
However, when the higher concentration (30 µmol/L)
was used to treat the RA, all 4 calcium channel antag-
onists nearly completely abolished the contraction
(Fig 2).
Discussion
In this study we found that in the human RA dihy-
dropyridine derivatives have higher potency than verap-
amil or diltiazem. Among the 4 calcium antagonists,
potency is in the following order: nifedipine > nicardi-
pine > verapamil > diltiazem. Therefore dihydropyri-
dine derivatives may have a role in CABG with the RA.
Furthermore, at high concentrations for topical use, any
one of the 4 calcium channel antagonists tested would
provide effective antispastic effect.
In the present study nifedipine is 19.5-fold more
potent than verapamil (P < .001) and 31.6-fold more
potent than diltiazem (P < .001) in the RA precontract-
ed with potassium. Its efficacy on prevention of RA
spasm is shown by the observation that at the usual
plasma concentration, nifedipine significantly reduced
RA contraction (from 138% to 87.7%, P < .001),
whereas neither verapamil nor diltiazem had any effect
on the RA contraction at an equal (for verapamil) or
higher (for diltiazem) concentration (Table II).
Therefore nifedipine expressed a better spasmolytic
effect in the RA than verapamil or diltiazem in 2 ways:
it is more potent in reversing existing contraction, as
well as in preventing contraction in RA. Cable and col-
leagues18 also reported that diltiazem has little effect on
human RA contraction.
Another dihydropyridine derivative, nicardipine, also
expressed a better spasmolytic effect than either vera-
pamil or diltiazem. Although nicardipine-induced
relaxation in potassium precontraction is only margin-
ally more potent than that of verapamil (2.2-fold high-
er, P = .8) and diltiazem (3.6-fold higher, P = .5), it
showed a significant depressive effect on the potassi-
um-induced contraction (from 138.6% to 101%, P =
.003; Table II) at the plasma concentration when used
before contraction to prevent it. In contrast, as men-
tioned above, neither verapamil nor diltiazem showed
any depressive effect on such contraction at the plasma
contraction, which is the same for verapamil as for
nifedipine and nicardipine and is even 3-fold higher for
diltiazem.
In the present study the depression effect on the RA
contraction was examined at 2 concentrations. The
experiment at the plasma concentration is essential to
simulate the clinical condition when systemic adminis-
tration of calcium channel antagonists is given. The
Table II. Inhibitory effect of calcium channel antagonists at the plasma concentration on the maximal contraction
(expressed as percentage of 100 mmol/L KCl-induced contraction) to potassium in the human RA
Control Nifedipine Nicardipine Verapamil Diltiazem
Emax 138.6 ± 5.7 87.7 ± 6.8 101.4 ± 7.6 140.3 ± 15.2 132.8 ± 7.3
95% CI of the mean difference of Emax — 31.0 to 70.8 15.9 to 58.5 –37.9 to 34.4 –15.0 to 26.6
compared with nifedipine
P value* — .0002 .003 .9 .5
Emax, Maximal concentration.
*Compared with the control by using the unpaired t test.
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study on another concentration (as high as 30 µmol/L,
which is not achievable by systemic administration) is
to simulate the clinical situation when topical use of
calcium channel antagonists is indicated. As expected
at such a high concentration, all 4 calcium channel
antagonists have superior depressive effects on the
A B
C D
Fig 2. Mean concentration (–log10 M)-contraction (percentage of 100 mmol/L potassium-induced contraction)
curves for 4 calcium channel antagonists: nifedipine (NIF, A), nicardipine (NIC, B), verapamil (VER, C), and dil-
tiazem (DIL, D). Rings taken from the same patient were allocated to each treatment. One ring was the control
(filled circles) without pretreatment of calcium antagonists. The second ring was treated with the plasma con-
centration of the particular calcium channel antagonists (open circles): 20 nmol/L (–7.7 log10 M) for nifedipine (A),
nicardipine (B), and verapamil (C) and 60 nmol/L (–7.2 log10 M) for diltiazem (D). The third ring was treated with
a high concentration of the calcium channel antagonists (filled triangles, 30 µmol/L [–4.5 log10 M]), which implies
the topical use of the drug. The drug was added into the organ bath 20 minutes before the start of the concentration-
contraction curve. Symbols represent data averaged from 6 rings (from 6 patients) for each calcium antagonist.
Vertical error bars are 1 SEM of mean values (P = .0002 for nifedipine [A], P = .003 for nicardipine [B], P = .9 for
verapamil [C], and P = .5 for diltiazem [D]; ANOVA). *P < .05; **P < .01; ***P < .001 compared with control
(Scheffe F test).
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potassium-induced contraction. This implies that for
topical use at high concentrations, any one of the calci-
um channel antagonists tested would provide effective
antispastic effect.
To compare the effect of the 4 calcium antagonists, in
the present study we used KCl as the precontraction
agent, as well as the agent to test the depression effect
on contraction. This is due to the fact that calcium
channel antagonists are selective vasodilators that
selectively inhibit the voltage-dependent calcium chan-
nel in human arteries.12 Potassium induces vascular
contraction through depolarizing the smooth muscle
membrane and therefore increases the membrane
potential that subsequently opens the voltage-depen-
dent calcium channel.12,13 Therefore calcium channel
antagonists are particularly effective in inhibition
of potassium-induced contraction, and this has been
shown in human vessels, such as the ITA12 and saphe-
nous vein.19 On the other hand, calcium channel antag-
onists are less effective to inhibit vascular contraction
mediated by receptor mechanisms.12,20,21 By using
potassium as the contraction agent, we may investigate
the maximal effect of calcium channel antagonists, and
this would provide an excellent basis to compare the
effect among various calcium antagonists. As seen in
the present study, all 4 calcium channel antagonists
induced a full or nearly full relaxation, and therefore
the potency (expressed by EC50) among those calcium
channel antagonists can be accurately compared.
In Acar and colleagues’4 protocol for RA grafting,
diltiazem is used as the systemic spasmolytic agent. In
contrast, we have been using verapamil in our clinical
protocol for RA grafting because nifedipine is not
available for intravenous infusion, and we believe that
verapamil is more potent than diltiazem on the basis of
data from previous studies on the ITA12 and saphenous
vein.14,19 However, both verapamil and diltiazem have
a negative chronotropic effect that induces brady-
cardia in some patients, particularly when used in
combination with β-blockers. The present study pro-
vides a scientific basis for the claim that dihydropyri-
dine derivatives may be used as systemic spasmolytic
agents instead of verapamil or diltiazem for a potent
effect. In our practice, if the patient cannot tolerate oral
verapamil postoperatively because of bradycardia,
nifedipine is used instead. Because of the fact that
nifedipine is not available for intravenous infusion,
nicardipine may be recommended for systemic use
intraoperatively.
Finally, the necessity of use of diltiazem or other cal-
cium channel antagonists perioperatively for RA
grafting is questioned.18 However, RA graft spasm is
encountered frequently if no vasodilators are used.4-6,9,11
Continuous search for the best regimen to overcome
RA spasm is clinically important.
In conclusion, the results from our in vitro study sug-
gest that dihydropyridine derivatives are highly potent
spasmolytic agents in the human RA. Among the 4 cal-
cium antagonists, the potency is in the following order:
nifedipine > nicardipine > verapamil > diltiazem.
Therefore dihydropyridine derivatives may be recom-
mended for systemic administration in CABG with
RA. Furthermore, at high concentrations for topical
use, any one of the 4 calcium channel antagonists test-
ed would provide effective antispastic effect.
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